Other Events ·
On June 11, 2026, BioCryst Pharmaceuticals stockholders approved a proposal to amend and restate the Stock Incentive…
BCRXBiocryst Pharmaceuticals Inc
On June 11, 2026, BioCryst Pharmaceuticals stockholders approved a proposal to amend and restate the Stock Incentive Plan, increasing the number of shares available for issuance by 7,000,000 shares. The company also elected directors Theresa M. Heggie, Amy E. McKee, and Jon P. Stonehouse, ratified Ernst & Young LLP as independent auditors, and passed a non-binding advisory vote on executive compensation. BioCryst Pharmaceuticals is a biopharmaceutical company that develops and commercializes medicines for rare diseases.